Methods and compositions for treating male erectile dysfunction

• US 7,265,091 B2
• Filed: 01/21/2005
• Issued: 09/04/2007
• Est. Priority Date: 07/21/2000
• Status: Expired due to Fees

• Current Assignee: Regents of the University of California (University of California)
• Original Assignee: Regents of the University of California (University of California)
• Inventors: Lue, Tom F., Kan, Yuet W., Carroll, Peter, Lin, Ching-Shwun
• Primary Examiner(s): Nickol; Gary B.
• Assistant Examiner(s): Gamett; Daniel C
• Application Number:
  US11/040,947
• Publication Number:
  US 20050233962A1
• Time in Patent Office: 956 Days
• Field of Search: None
• US Class Current: 514/8.1
• CPC Class Codes: A61K 38/1825 Fibroblast growth factor [FGF]
• CPC Class Codes: A61K 38/185 Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
• CPC Class Codes: A61K 38/1858 Platelet-derived growth factor [PDGF]
• CPC Class Codes: A61K 38/1866 Vascular endothelial growth factor [VEGF]
• CPC Class Codes: A61K 38/1891 Angiogenesic factors; Angiogenin
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: G01N 33/50 Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing measuring or testing processes involving enzymes or microorganisms, compositions or test papers therefor; processes for forming such compositions, condition responsive control in microbiological or enzymological processes C12Q

Abstract

The invention provides a method for preventing or treating male erectile dysfunction or female sexual arousal disorder by administering an effective amount of one or more factors from a group of factors including vascular endothelial growth factor, brain-derived neurotrophic factor, basic fibroblast growth factor, neurotrophin-3, neurotrophin-4, or angiopoietin-1, wherein the factor is a full length protein or a nucleic acid encoding the factor, or a functional derivative or fragment thereof, or an agent that enhances production and/or male erection or female sexual arousal stimulating function of the factor(s). Combinations, kits, and combinatorial methods are also provided.

Claims

1. A method for treating male erectile dysfunction, comprising administering to a mammal to whom such treatment is needed or desirable, a combination comprising:

a) an effective amount of vascular endothelial growth factor (VEGF), wherein the VEGF is a full length protein; and

b) an effective amount of a factor protein selected from the group consisting of brain-derived growth factor (BDNF), neurotrophin-3 (NT-3), and neurotrophin-4 (NT-4), wherein the factor protein is a full length protein;

thereby treating the male erectile dysfunction in the mammal.

2. The method of claim 1, wherein the mammal is a human and the factor is of human origin.

3. The method of claim 1, wherein the factor protein is administered by intracavernous injection, subcutaneous injection, intravenous injection, intramuscular injection, intradermal injection, or topical administration.

4. The method of claim 1, wherein the factor protein is administered via a liposome.

5. The method of claim 1, wherein the factor protein is administered in an amount sufficient to improve blood flow and regenerate nerve fibers in the penis.

6. The method of claim 1, wherein the factor protein is administered by intracavernous injection.

7. The method of claim 1, wherein the combination is in the form of a pharmaceutical composition.

8. The method of claim 7, wherein the combination further comprises a pharmaceutically acceptable carrier or excipient.

9. The method of claim 1, wherein the combination consists essentially of VEGF and BDNF.

10. The method of claim 9, wherein the dose of each factor protein in the combination is 10-200 mcg/70 kg body weight administered once every two to six months.